Medpace Laboratories, Singapore will serve and support new and existing Medpace pharmaceutical clients conducting clinical research in the rapidly expanding Asia Pacific region.
Quintiles and Covance have re-iterated previous CROs’ upbeat stances on the prospect for further pharma M&A as they both reported revenue growth for the quarter.
Boehringer Ingelheim says the Saudi Arabian market is a huge drive for big pharma as it teams with local firms to manufacture secondary packaging for 26 products.
Bayer says it will become the OTC leader in North America having acquired Merck & Co.’s consumer health business for $14.2bn (€10.2bn), in the latest shift in Big Pharma assets.
Hospira says approval for its new manufacturing facility in India is still on track despite receiving a Form 483 form the US FDA with ten observations.
Experts have predicted emerging Indian and Chinese markets will outpace Western markets as the $2.3bn oral solid dosage form (OSDF) excipients global market grows at a sustainable rate.
Capsugel is no longer a simple capsule provider but a differentiated player in the CDMO industry, the firm says as it wins a scale-up manufacturing contract for Chiasma and Roche’s oral octreotide candidate.
As regulators incentivise the development of orphan medicines and high price tags for the drugs continue to rise, logistics specialists are offering new ways to get the drugs to the increasingly small patient populations.
Toxicology services provider Harlan Laboratories has selected Invenium Pharmacology as its exclusive agent for Harlan’s Contract Research Services (CRS) in Australia, Southeast Asia and New Zealand.
A stake in Brazil-based wholesaler Profarma will increase AmerisourceBergen’ global presence already strengthened by the World Courier acquisition, the firm says as it reports a robust Q2.
As pharma manufacturers look to cut costs and increase quality, over 70% of industry executives interviewed for a recent CPhI report say they are actively investing in manufacturing techniques and technologies to achieve these goals.
The relationship between private equity (PE) management and that of its CRO is “pivotal,” according to the Chairman of one pharma group, as PE’s undefined objectives and exit strategies are leaving sponsors uncomfortable.
Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
SAS, a provider of tools for data and health analysis, will supply the platform for a project sharing oncology data from studies by AstraZeneca, Janssen R&D, Pfizer and Sanofi.
A new report says the Japanese CRO market is seeing more growth as Japanese pharma firms, which traditionally kept research in-house, are now broadening their horizons to use more outsourcing partners.
With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
Biopharma executives believe there will be strong growth in domestic R&D activities and biopharma manufacturing, but fewer workers will be needed as efficiencies in productivity are achieved across the industry, according to a new survey from industry...
Patient recruitment is “the major bottleneck” in clinical development, an Industry Standard Research report says, but though it predicts a drive to ‘push’ patients into trials, industry disagrees.
Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst firm Jeffries.
Roche has clashed with the authors of a report slamming the efficacy of Tamiflu, each claiming the other’s analysis of patient data is seriously flawed.
Tamiflu shortens the duration of influenza symptoms by only half a day, does not stop person-to-person spread and increases the risk of nausea say the authors of a new review who want Governments to rethink stockpiling neuraminidase inhibitors.
Genentech says its collaboration with PatientsLikeMe will enable more effective clinical trial recruitment but will not affect its partnerships with CROs.
CRO and sponsor payment service provider Clinverse announced a record first quarter to start 2014, with the addition of four significant new clients, as well as strong additional repeat business from existing clients.
Molecular Profiles has invested in hot melt extrusion (HME) and nano milling capabilities citing client demand for improving the bioavailablity of drugs.
Pharmaceutical companies will be made to publish all European clinical trials in a public database under a draft law passed by the European Parliament yesterday.
Pernix Therapeutics will no longer be a CMO as it has signed a definitive agreement to divest its Houston, Texas-based manufacturing operations to Woodfield Pharmaceutical to cut costs.
Quality and IP issues are driving firms back to the US and Europe for their contract manufacturing according to experts, but Kemwell says there are still opportunities for Indian CMOs.
BioReliance has updated its big blue assay for the second time in six months by creating a version of the drug genotoxicity test that can be used in rats.
Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.
AmerisourceBergen (ABC) plans to buy a minority stake in a Brazilian drug wholesaler and outlined plans for a $100m distribution services joint-venture in the rapidly expanding market.
Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.
Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.
US pharmaceutical firms ‘fear change’ and need guidance on assessing safe excipient supply to become more like their European counterparts, says a senior IPEC expert.
Aegis Therapeutics claims a technology developed to improve the bioavailability of drugs delivered through the nose has a similar solubility enhancement effect in a solid dosage form.
The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.
Aesica has predicted that CMO sector consolidation will continue and hinted that it is considering strategic acquisitions as a part of a bid to generate $1bn revenue.
Patheon brings fill/finish capabilities to DSM’s biomanufacturing services, President of Biopharma at the recently merged company DPx told Biopharma-Reporter.com in an exclusive interview.
In an exclusive interview, Patheon Executive Mike Lehmann talks DSM integration, further growth and how consolidation amongst CMOs may be driving strategic alliances with pharma.
As part of an effort to increase transparency, the EMA (European Medicines Agency) has published the first summary of a risk-management plan (RMP) of a newly authorised medicine.
